Market Overview

UPDATE: Morgan Stanley Initiates Infinity Pharmaceuticals at Overweight on Blood Cancer Drug Data

Related INFI
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
3 Partnerships Pushing The Pharmaceutical Sector Forward

Morgan Stanley initiated Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $47.00 price target.

Morgan Stanley noted, "Infinity's wholly-owned early stage IPI-145 for blood cancers has shown positive early data and is on track to figure significantly in an emerging BCR drug class with multi-billion dollar potential. 2013 holds multiple catalysts to further validate IPI-145's efficacy/safety."

Infinity Pharmaceuticals closed at $35.20 on Friday.

Latest Ratings for INFI

DateFirmActionFromTo
Oct 2014Stifel NicolausInitiates Coverage onHold
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform
Sep 2014JefferiesMaintainsBuy

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters